Board MeetingMay 12, 2026, 04:07 PM
Connect Biopharma to Present at H.C. Wainwright BioConnect Conference
AI Summary
Connect Biopharma Holdings Limited announced that its management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The presentation will be webcast live and an archived replay will be available for approximately 90 days. The company is a clinical-stage biopharmaceutical firm developing rademikibart for asthma and COPD, with an exclusive license agreement in Greater China that includes potential milestone payments up to $110 million and tiered royalties.
Key Highlights
- Management to present at H.C. Wainwright BioConnect Investor Conference.
- Fireside chat scheduled for May 19, 2026, at 9:30 a.m. ET.
- Live webcast available on Connect Biopharma's investor website.
- Archived replay accessible for approximately 90 days.
- Developing rademikibart for asthma and COPD.
- Potential remaining milestone payments up to $110 million from Simcere.
- Eligible for tiered royalties up to low double-digit percentages on Greater China sales.
Price Impact
More from CNTB